Inside the Phased, Risk-Based Approach for CGT Materials

Why It Matters

Standardized, risk‑based guidance for CGT raw materials will reduce development delays, lower contamination risks, and improve regulatory confidence across the industry.

Key Takeaways

• Bio4 developing guidance for particulates in raw materials.
• Cross‑committee collaboration brings diverse perspectives to particulate challenges.
• Early‑stage risk assessments should be lightweight, high‑level, and focused.
• Prioritize high‑risk materials for deeper analysis in later phases.
• Allocate sufficient time and resources for assay development before pivotal trials.

Summary

The video focuses on Bio4’s phased, risk‑based strategy for addressing particulate contamination in cell and gene therapy (CGT) raw and starting materials, a gap that has long plagued the industry. Bio4 is assembling a subgroup to draft best‑practice guidance, potentially as a chapter or white paper, and is partnering with other expert committees across modalities to pool expertise.

Key insights include the recognition that existing guidance is robust for drug‑product particulates but sparse for raw materials, prompting a collaborative effort to generate unified recommendations. The presenters advocate a “right‑sized” risk assessment: light, high‑level reviews in early development that evaluate bill‑of‑materials, supplier qualification, and patient‑safety red flags, followed by deeper, resource‑intensive analyses as programs advance toward pivotal trials.

Notable remarks underscore the urgency of time constraints, with one speaker noting, “time is everyone’s enemy,” and emphasizing the need to prioritize the highest‑risk materials first. The discussion also highlights the value of cross‑disciplinary input, suggesting that fresh perspectives can unlock solutions previously overlooked.

The implications are significant: clearer guidance will streamline CGT material qualification, reduce regulatory uncertainty, and enhance patient safety. Companies that adopt the phased risk‑assessment framework can better allocate resources, accelerate development timelines, and meet evolving compliance expectations.

Original Description

In this segment of Cell & Gene Live, Anthony Blaszczyk, Ph.D., Senior Scientist at the U.S. Pharmacopeia, and Basak Clements, Ph.D., Founder and Senior Advisor at biomatria, were joined by Cell & Gene Chief Editor Erin Harris to discuss the efforts that are underway to close the gap in particulate guidance for cell and gene therapy by developing new best practices and fostering cross-industry collaboration, recognizing that particulates remain a complex, unsolved challenge.